Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Trinity Biotech announces Results for Q1, 2018

Posted on: 01 May 18

DUBLIN, Ireland, May 01, 2018 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2018.

Quarter 1 Results
Total revenues for Q1, 2018 were $23.8m which compares to $23.5m in Q1, 2017, an increase of $0.3m and were broken down as follows:

Quarter 1
Quarter 1
Clinical Laboratory19,52620,0232.5%

Point-of-Care revenues for Q1, 2018 decreased from $4.0m to $3.8m when compared to Q1, 2017, a reduction of 5.8%. This was due to a combination of the impact of lower public health spending on U.S. HIV sales and the normal fluctuation of African HIV orders.

Clinical Laboratory revenues increased from $19.5m to $20.0m, which represents an increase of 2.5% compared to Q1 2017. As has been the case in previous quarters, this growth was due to higher Diabetes and Autoimmunity sales.

Gross profit for Q1, 2018 amounted to $10.4m representing a gross margin of 43.8%. This was higher than the 42% achieved in Q1, 2017 and was higher than the gross margin reported in each of the subsequent quarters of 2017.

Research and Development expenses remained flat at $1.3m whilst Selling, General and Administrative (SG&A) fell slightly from $7.0m to $6.9m during the quarter.

Operating profit for the quarter was $1.8m, which is higher than the $1.3m achieved in Q1, 2017 and this was attributable to the combination of the higher revenues and improved gross margin.

Financing income for the quarter was marginally higher at $0.2m reflecting higher available deposit interest rates. Meanwhile, interest payable, mainly arising on the Company’s exchangeable notes, remained static at $1.2m.  A further non-cash expense of $0.3m was recognised in the quarter.  This was due to a loss of $0.1m arising on an increase in the fair value of the embedded derivatives associated with the exchangeable notes plus non-cash interest of $0.2m.
The profit after tax, before non-cash financial expenses, for the quarter was $0.7m and compares favourably to $0.2m for the equivalent period last year.  This was primarily due to the improved operating profit this quarter.    

The basic EPS (excluding non-cash financial expenses) for the quarter was 3.4 cents versus 1.0 cent in Q1, 2017. Unconstrained diluted EPS for the quarter amounted to 7.1 cents, which compares to 5.0 cents in the equivalent quarter in 2017.

Earnings before interest, tax, depreciation, amortisation and share option expense for the quarter was $3.3m, compared with $2.7m in Q1, 2017.

Share Buyback

During the quarter, the Company bought back 27,000 shares at an average price of $5.15 and a total value of $0.1m. This brings the total purchased since the beginning of the program to over 2.5m shares with a total value of $17.5m.


Commenting on the results, Kevin Tansley, Chief Financial Officer stated, “There were a number of positive aspects to our performance this quarter. In addition to our growth in revenues, we saw a significant improvement in gross margins to 43.8%, which is the highest we have recorded in the last six quarters.  By maintaining the level of our indirect costs, this translated into an increase in operating profit from $1.3m to $1.8m – an increase of over 38%.  Similarly our Diluted EPS increased from 5 cents to 7.1 cents.”

Ronan O’Caoimh, Chief Executive Officer stated, “Clinical Laboratory revenues grew by 2.5% this quarter. As in previous quarters, this was driven by the continued growth of our Diabetes and Autoimmunity businesses. Meanwhile, our Point-of-Care revenues fell by 5.8%. This partly due to the adverse impact of lower federal funding for public health programs on US HIV revenues.  In addition, African HIV sales were slightly lower this quarter due to the normal fluctuations which are a feature of this market.  Of greater importance is the fact that Trinity’s Uni-gold product remains the pre-eminent confirmatory HIV test in the African market.”

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website:

Trinity Biotech plc
Consolidated Income Statements

(US$000’s  except share data) Three Months
Mar 31,
 Three Months
Mar 31,
Revenues 23,799 23,536 
Cost of sales (13,371)(13,645)
Gross profit  10,428 9,891 
Gross profit % 43.8% 42.0% 
Other operating income 24 23 
Research & development expenses (1,272)(1,328)
Selling, general and administrative expenses (6,940)(7,028)
Indirect share based payments (434)(250)
Operating profit  1,806 1,308 
Financial income 205 177 
Financial expenses (1,159)(1,170)
Net financing expense (954)(993)
Profit before tax & non-cash items 852  315 
Income tax expense (132)(99)
Profit after tax before non-cash items 720 216 
Non-cash financial (expense)/income (342)1,030 
Profit after tax and non-cash items 378 1,246 
Earnings per ADR (US cents) 1.8 5.6 
Earnings per ADR excluding non-cash financial expense/income (US cents) 3.4 1.0 
Diluted earnings per ADR (US cents)* 7.1 5.0 
Weighted average no. of ADRs used in computing basic earnings per ADR 20,907,885 22,102,620 
Weighted average no. of ADRs used in computing diluted earnings per ADR 26,163,828 27,362,174 

* Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. In a reporting period where it is anti-dilutive, diluted earnings per ADR should be constrained to equal basic earnings per ADR.

The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).

Trinity Biotech plc
Consolidated Balance Sheets

 Mar 31,
US$ ‘000
Dec 31,
US$ ‘000
Non-current assets  
Property, plant and equipment7,0335,800
Goodwill and intangible assets66,47464,754
Deferred tax assets8,9688,698
Other assets779771
Total non-current assets83,25480,023
Current assets  
Trade and other receivables22,11820,740
Income tax receivable1,2341,440
Cash, cash equivalents and deposits53,89557,607
Total current assets111,426112,592
TOTAL ASSETS194,680192,615
Equity attributable to the equity holders of the parent  
Share capital1,2241,224
Share premium16,18716,187
Accumulated surplus46,83746,157
Other reserves1,5291,628
Total equity65,77765,196
Current liabilities  
Income tax payable344310
Trade and other payables21,76120,845
Total current liabilities22,15521,230
Non-current liabilities  
Exchangeable senior note payable95,16794,825
Other payables453532
Deferred tax liabilities11,12810,832
Total non-current liabilities106,748106,189

The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).

Trinity Biotech plc
Consolidated Statement of Cash Flows

(US$000’s)Three Months
Mar 31,
  Three Months
Mar 31,
Cash and cash equivalents at beginning of period57,607  77,108 
Operating cash flows before changes in working capital3,258  2,267 
Changes in working capital(2,679) (2,208)
Cash generated from operations579  59 
Net Interest and Income taxes paid204  177 
Capital Expenditure & Financing (net)(4,061) (3,646)
Free cash flow(3,278) (3,410)
Payment of HIV-2 licence fee-  (1,112)
Share buyback(434) (1,833)
Once-off items-  (902)
Cash and cash equivalents at end of period53,895  69,851 

The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).

Contact:Trinity Biotech plcLytham Partners LLC
 Kevin TansleyJoe Diaz, Joe Dorame & Robert Blum

Last updated on: 01/05/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.